Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab

Authors

Robin L. Avila
Flavia Nelson (ORCID: https://orcid.org/0000-0003-2850-5572)
Karen Blitz-Shabbir
Aimee Banks (ORCID: https://orcid.org/0000-0001-6134-7364)
Jason P. Mendoza (ORCID: https://orcid.org/0000-0003-2526-5542)
Nicholas Belviso
Hina Garg (ORCID: https://orcid.org/0000-0001-5828-303X)
Kinyee Fong
Suma Shah (ORCID: https://orcid.org/0000-0003-3989-944X)
Boyang Bian (ORCID: https://orcid.org/0000-0003-0153-4218)

Institutions

Biogen (United States) (US)
NewYork–Presbyterian Brooklyn Methodist Hospital (US)
University of Miami (US)
Duke University (US)
Rocky Mountain University of Health Professions (US)
Vanderbilt University Medical Center (US)

Publication Details

Journal: Drugs - Real World Outcomes
Published: 2025-05-30
DOI: https://doi.org/10.1007/s40801-025-00495-w
Primary Topic: Multiple Sclerosis Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Biogen

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab

Robin L. Avila, Flavia Nelson, Karen Blitz-Shabbir, Aimee Banks et al.

May 30, 2025

Drugs - Real World Outcomes

Multiple Sclerosis Research Studies

article

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab

Robin L. Avila, Flavia Nelson, Karen Blitz-Shabbir, Aimee Banks, Jason P. Mendoza, Nicholas Belviso, Hina Garg, Kinyee Fong, Suma Shah, Boyang Bian

May 30, 2025article en

Abstract

No abstract available for this paper.

Drugs - Real World OutcomesVol. 12(2)

Biogen (United States) (US), NewYork–Presbyterian Brooklyn Methodist Hospital (US), University of Miami (US), Duke University (US), Rocky Mountain University of Health Professions (US), Vanderbilt University Medical Center (US)

Biogen

Good health and well-being

Openalex Percentile: Top 83%

Multiple Sclerosis Research Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab — Robin L. Avila, Flavia Nelson, et al. · Drugs - Real World Outcomes (2025) | TGRS Research Map | TGRS